{
    "symbol": "CEMI",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 14:19:01",
    "content": " In the second quarter, we generated total revenue of $9.2 million, including product revenue of $8.9 million, representing growth of 42% and 125%, respectively, compared to the prior year period. United States product sales in the second quarter totaled $3.4 million, growing 208% compared to the prior year period. For the three months ended June 30, 2022, total revenue was $9.2 million, representing growth of 42% compared to the prior year period. Product revenue for the second quarter of 2022 was $8.9 million, an increase of 125% compared to the prior year period. Government grant income, license and royalty revenues and R&D revenues combined for the three months ended June 30, 2022, were $0.3 million, a decrease of 88% compared to the prior year period, due to the expiration of previous partner development agreements. Our revenues were in compliance with the quarterly 12-month rolling minimum total revenue covenants in our credit agreement Gross product margins during the three months ended June 30, 2022, increased to $0.8 million, compared to negative $0.1 million in the prior year period. R&D costs decreased by $0.8 million compared to the prior year period to $2 million in the second quarter of 2022, primarily associated with completion of development work from prior partnership development agreements. Selling, general and administrative expenses decreased by $0.8 million compared to the prior year period to $5.2 million in the second quarter of 2022, primarily attributable to lower legal costs."
}